Suven Life Sciences shows a concerning trend in financial performance. The compounded sales growth has been negative across 3, 5, and 10-year periods. The recent TTM sales growth is at -43%, indicating a significant decline in revenue generation. Similarly, profit growth is negative across all measured periods, with the TTM profit growth at -37%. OPM% is significantly negative, reaching -2,489% in Mar 2025, indicating operational inefficiencies. Net profits are consistently negative, with a net loss of ₹161 Cr in Mar 2025. The company's core operations are not generating profits, relying on other income, which is inconsistent and insufficient to offset losses.

The company's capital efficiency and returns are significantly weak. ROCE is -84% as of Mar 2025, indicating poor capital utilization. ROE is also negative, at -85% for the same period, showing that shareholder funds are not yielding good returns. The negative ROCE and ROE values underscore that the company is not effectively using its capital to generate profits, leading to poor returns for its shareholders. This situation is further compounded by inconsistent sales and profit figures, indicating a lack of stability in the company's financial performance.

Suven Life Sciences exhibits varied indicators of financial health. The company has minimal debt, with borrowings consistently decreasing to ₹0 Cr by Mar 2025. This suggests a conservative approach to leverage. However, the interest coverage ratio cannot be reliably assessed due to operating losses. The company has ceased dividend payouts since Mar 2018, indicating a focus on conserving funds. Despite low debt, the company's persistent losses raise concerns about its long-term financial sustainability. The absence of debt reduces immediate financial risk, but the inability to generate profits remains a critical issue.

The shareholding pattern of Suven Life Sciences indicates strong promoter confidence, with promoter holding increasing to 70.26% by Mar 2025. However, there has been a decrease in FII holdings, dropping to 0.25% by Mar 2025. DII holdings are minimal, at 0.01% for the same period. The increase in promoter holding suggests a strong commitment from the company's management, but the declining interest from FIIs and DIIs could be a concern. The high promoter stake provides stability, but the lack of institutional interest may reflect concerns about the company's financial performance.

Assessing segment-specific performance volatility is challenging. The inconsistent sales and profit figures indicate a lack of stability. Fluctuations in quarterly results, such as significant variations in YOY Sales Growth %, suggest operational instability. Consistent negative profit margins and volatile sales figures highlight the need for better segment performance management to ensure overall financial health.

Based on available data, there is no explicit mention of significant foreign exchange exposure, the company's borrowings are minimal, reducing interest rate exposure. The absence of substantial debt mitigates risks associated with interest rate fluctuations.

There is no direct data available regarding regulatory compliance cost trends. However, increasing expenses relative to sales could imply rising compliance costs, especially in the pharmaceutical industry. Without specific figures, it is challenging to definitively assess this risk.